A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : IMT / immunomodulatory therapy

[Related PubMed/MEDLINE]
Total Number of Papers: 54
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   IMT  (>> Co-occurring Abbreviation)
Long Form:   immunomodulatory therapy
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Histoplasmosis Following Systemic Immunomodulatory Therapy for Ocular Inflammation. ---
2019 Management of advanced ocular surface disease in patients with severe atopic keratoconjunctivitis. AKC, LSCD
2019 Real-world evidence of treatment for relapse of noninfectious uveitis in tertiary centers in Japan: A multicenter study. AAU, AI, BD, CS, ED, JIA, ME, NIU, OPN, RV, SRD, STTA, TINU, VKH, VO
2019 Relapse of Juvenile Idiopathic Arthritis-Associated Uveitis after Discontinuation of Immunomodulatory Therapy. JIA
2018 Immune-mediated neurological manifestations of dengue virus- a study of clinico-investigational variability, predictors of neuraxial involvement, and outcome with the role of immunomodulation. DF, DHF, DSS, GBS, IMCD, IMNC, MFS
2018 Long-term remission of ocular cicatricial pemphigoid off immunomodulatory therapy. OCP
2018 Outcomes of "Early" Withdrawal of Corticosteroid Sparing Immunomodulatory Therapy for Birdshot Retinochoroidopathy. BSRC
2018 Pathologic Markers Determining Prognosis in Patients With Treated or Healing Giant Cell Arteritis. GCA, ROC, SD, TABs
2018 Repeat Conjunctival Biopsy after Immunomodulatory Therapy for Ocular Mucous Membrane Pemphigoid. MMP
10  2018 Systemic immunosuppression and risk of age-related macular degeneration. AMD, CKD
11  2018 Use of Immunosuppressive Medications for Treatment of Pediatric Intermediate Uveitis. IU
12  2017 A review and update on orphan drugs for the treatment of noninfectious uveitis. FDA
14  2017 Treatment Results in Serpiginous Choroiditis and Multifocal Serpiginoid Choroiditis Associated with Latent Tuberculosis. ATT, CS, MSC, SC
15  2016 A national survey of Canadian ophthalmologists to determine awareness of published guidelines for the management of uveitis. ---
16  2016 Chronic Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: The Role of Systemic Immunomodulatory Therapy. SJS, TEN
17  2016 Interleukin-22 serum levels are elevated in active scleritis. IL, Th
18  2016 Posterior Uveitis. CS
19  2015 Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis. BL, IVT, IVT, NEI VFQ-39, QOL, SCJ, SCJ
20  2015 Diagnosis of latent tuberculosis infection with T-SPOT().TB in a predominantly immigrant population with rheumatologic disorders. LTBI, TSPOT, TST
21  2015 Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. GC, VA
22  2015 Immunomodulatory therapy in refractory/recurrent ovarian cancer. ALC, EOC, SD
23  2014 Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study. CRIM, ERT
24  2013 Immunomodulators for multiple sclerosis may ameliorate spinal bone loss. BMD, BTM, MS
25  2013 Interleukin-17 production and T helper 17 cells in peripheral blood mononuclear cells in response to ocular lysate in patients with birdshot chorioretinopathy. BSCR, IFN-gamma, IL-17, PBMCs, Th17
26  2013 Risk factors associated with the relapse of uveitis in patients with juvenile idiopathic arthritis: a preliminary report. JIA
27  2013 Vogt-Koyanagi-Harada syndrome. VKHS
28  2012 Immune Modulation Therapy in a CRIM-Positive and IgG Antibody-Positive Infant with Pompe Disease Treated with Alglucosidase Alfa: A Case Report. CRIM, ERT
29  2012 Scleritis therapy. BRMs, NSAIDs, OR, SAIDs
30  2011 Importance of proper diagnosis for management: multifocal choroiditis mimicking ocular histoplasmosis syndrome. MFC, OHS
31  2011 Mycophenolate mofetil and fundus autofluorescence in the management of recurrent punctate inner choroidopathy. FAF, MMF, PIC
32  2010 Pars plana vitrectomy versus immunomodulatory therapy for intermediate uveitis: a prospective, randomized pilot study. CME, IU, PPV, VA
33  2010 Use of a non-specific immunomodulation therapy as a therapeutic vasculogenesis strategy in no-option critical limb ischemia patients. CLI, EPCs
34  2009 Choroidal folds in acute Vogt-Koyanagi-Harada disease. BCV, CFs, VKH
35  2009 Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study). MS
36  2009 Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. BMD, DXA, MS
37  2009 Induction of durable remission in ocular inflammatory diseases. ---
38  2008 Daclizumab for treatment of birdshot chorioretinopathy. BSCR, ERG
39  2008 Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. LV, NYHA
40  2007 Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management. ---
41  2007 Infliximab therapy for the treatment of refractory ocular inflammatory disease. ---
42  2007 Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. MS
43  2006 Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. VKH
44  2005 Biologic effects and basic science of a novel immune-modulation therapy. CHF, IL, TNF-alpha
45  2005 Evidence of an anti-inflammatory role for Vasogen's immune modulation therapy. ---
46  2005 Immune activation in chronic heart failure. CHF, IL, IVIG, TNF-alpha
47  2005 Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. ---
48  2005 Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. BSRC, ERGs, VAs
49  2005 Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid-resistant juvenile idiopathic arthritis-associated chronic iridocyclitis. IA
50  2004 Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. HF, NYHA
51  2003 Vasogen's immune modulation therapy (IMT) improves postischemic foot skin blood flow and transcutaneous pO(2) recovery rates in patients with advanced peripheral arterial occlusive disease. LDF, PAOD
52  2002 A randomised, double blind, placebo-controlled study to determine the efficacy of immune modulation therapy in the treatment of patients suffering from peripheral arterial occlusive disease with intermittent claudication. ICD
53  2002 Attenuation of LPS-induced changes in synaptic activity in rat hippocampus by Vasogen's Immune Modulation Therapy. LPS
54  2002 Renal ischemia-reperfusion injury in the rat is prevented by a novel immune modulation therapy. I/R, SHR, UV